Insulin Resistance Clinical Trial
Official title:
Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies
Obesity is a strong risk factor for developing type 2 diabetes (T2DM), but the reasons for
this are not fully understood. In particular, it is not known why some obese people develop
T2DM while other obese individuals do not. This study tests whether differences in fat cells
(adipocytes) are to blame. Even in adults, fat cells are constantly being formed to replace
old fat cells and to respond to the body's need to store excess energy. The ability to form
new fat cells may be diminished in some individuals, leading to larger fat cells. These
large fat cells secrete hormones that may increase risk for T2DM. This study tests whether
fat cells from obese insulin resistant subjects (who are at risk for developing T2DM) form
at a slower rate than those from insulin sensitive subjects (who are at lower risk for
developing T2DM).
To address this question we will recruit and study two groups of obese subjects, selected to
be similar in age, gender and degree of obesity. One group of subjects will be obese and
insulin resistant (the OIR group), while the other will be comparably obese, but insulin
sensitive (OIS). Subjects will undergo a series of studies to characterize their metabolism
including measurement of body fat by DEXA scanning, oral glucose tolerance (a test used to
diagnose diabetes) and measurement of insulin sensitivity in response to an infusion of
insulin (a research study used to classify patients into the OIR and OIS groups). Small
samples of fat (from just under the skin of the belly and the buttocks) will obtained using
a needle on two occasions over 12 weeks. During these 12 weeks, subjects will drink a small
amount of water that contains a non-radioactive label. This labeled water will allow us to
measure the rate of growth of new fat cells in the body. We will also look at the rate of
growth of fat cells obtained from these biopsies in the laboratory.
The results of this study may tell us more about why certain obese people develop diabetes
and why others do not. This might lead to new ways to prevent or treat T2DM.
Overview of design: To address the specific aims of this study we will recruit and study two
groups of obese subjects, selected to be similar in age, gender and BMI. Based on the
results of an oral glucose tolerance test (OGTT) and hyperinsulinemic-glucose clamp, one
group will be obese and insulin resistant (OIR) and one will be obese and insulin sensitive
(OIS). Subjects will undergo measurement of body fat and fat distribution, oral glucose
tolerance, in vivo insulin sensitivity, percutaneous needle biopsies of subcutaneous
abdominal and gluteal fat and in vivo measurement of SVC and adipocyte turnover using the
D2O DNA labeling technique. Adipocyte size and the expression of pro-inflammatory cytokines
and adipokines will be compared in the two groups. Primary cultures of preadipocytes will be
derived from subjects and proliferation and differentiation measured in vitro and compared
to in vivo measures.
Measurement of adipocyte proliferation and differentiation in vivo: The stable isotope
technique of Hellerstein et al. for the measurement of slowly dividing cells is based on the
incorporation of deuterium oxide (D2O) into DNA. This method has been used to estimate rates
of turnover of adipocytes and stromal vascular cells in healthy normal volunteers. It has
not, to date, been employed to compare groups of subjects who may differ in their adipogenic
propensity. A major objective of the study, therefore, is to evaluate the utility of this
approach for quantifying in vivo differences in adipocyte and SVC turnover between groups
that vary by insulin sensitivity and to compare the in vivo measures obtained using this
technique with in vitro measures of adipogenesis.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
| Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
| Recruiting |
NCT05354245 -
Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)
|
N/A | |
| Completed |
NCT03383822 -
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
| Completed |
NCT04203238 -
Potato Research for Enhancing Metabolic Outcomes
|
N/A | |
| Recruiting |
NCT03658564 -
Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance
|
N/A | |
| Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
| Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Completed |
NCT03627104 -
Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity
|
N/A | |
| Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
| Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
| Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
| Completed |
NCT01809288 -
Identifying Risk for Diabetes and Heart Disease in Women
|
||
| Completed |
NCT04642482 -
Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity
|
Phase 4 | |
| Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
| Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
| Withdrawn |
NCT04741204 -
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer
|
Phase 4 | |
| Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A |